DaVita Valuation
Is DVA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DVA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DVA * (MX$3113.21) is trading below our estimate of fair value (MX$6451.08)
Significantly Below Fair Value: DVA * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DVA *?
Key metric: As DVA * is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is DVA *'s PE Ratio? | |
|---|---|
| PE Ratio | 15.9x |
| Earnings | US$827.68m |
| Market Cap | US$12.66b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 9.6x |
| PEG Ratio | 3.7x |
Price to Earnings Ratio vs Peers
How does DVA *'s PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23x | ||
FME Fresenius Medical Care | 18.6x | 19.3% | €12.3b |
CHE Chemed | 27.6x | 8.8% | US$8.4b |
SHL Sonic Healthcare | 24.3x | 11.0% | AU$12.4b |
DGX Quest Diagnostics | 21.4x | 11.7% | US$17.5b |
DVA * DaVita | 15.9x | 4.3% | Mex$12.7b |
Price-To-Earnings vs Peers: DVA * is good value based on its Price-To-Earnings Ratio (15.9x) compared to the peer average (23x).
Price to Earnings Ratio vs Industry
How does DVA *'s PE Ratio compare vs other companies in the Global Healthcare Industry?
| 13 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 13 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: DVA * is good value based on its Price-To-Earnings Ratio (15.9x) compared to the Global Healthcare industry average (20.7x).
Price to Earnings Ratio vs Fair Ratio
What is DVA *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DVA *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | n/a | Mex$3,152.64 0% | 10.1% | Mex$3,737.30 | Mex$2,692.46 | n/a | 9 |
| Nov ’25 | Mex$3,113.21 | Mex$3,151.67 +1.2% | 10.4% | Mex$3,722.98 | Mex$2,682.14 | n/a | 9 |
| Oct ’25 | n/a | Mex$2,981.90 0% | 8.0% | Mex$3,407.88 | Mex$2,609.46 | n/a | 8 |
| Sep ’25 | n/a | Mex$2,819.69 0% | 10.2% | Mex$3,324.27 | Mex$2,345.98 | n/a | 8 |
| Aug ’25 | n/a | Mex$2,636.34 0% | 10.0% | Mex$3,103.47 | Mex$2,240.37 | n/a | 8 |
| Jul ’25 | Mex$2,535.00 | Mex$2,372.67 -6.4% | 10.0% | Mex$2,820.09 | Mex$2,035.80 | n/a | 8 |
| Jun ’25 | n/a | Mex$2,372.67 0% | 10.0% | Mex$2,820.09 | Mex$2,035.80 | n/a | 8 |
| May ’25 | n/a | Mex$2,195.29 0% | 5.9% | Mex$2,437.55 | Mex$2,013.92 | n/a | 9 |
| Apr ’25 | n/a | Mex$2,195.29 0% | 5.9% | Mex$2,437.55 | Mex$2,013.92 | n/a | 9 |
| Mar ’25 | n/a | Mex$2,191.56 0% | 6.7% | Mex$2,474.66 | Mex$2,044.58 | n/a | 8 |
| Feb ’25 | n/a | Mex$1,839.06 0% | 8.6% | Mex$2,036.33 | Mex$1,527.25 | n/a | 8 |
| Jan ’25 | n/a | Mex$1,813.40 0% | 7.2% | Mex$1,979.04 | Mex$1,548.81 | n/a | 8 |
| Dec ’24 | n/a | Mex$1,797.85 0% | 6.5% | Mex$1,946.41 | Mex$1,550.24 | n/a | 8 |
| Nov ’24 | n/a | Mex$1,978.01 0% | 11.2% | Mex$2,533.28 | Mex$1,784.00 | Mex$3,113.21 | 8 |
| Oct ’24 | n/a | Mex$1,996.90 0% | 10.4% | Mex$2,492.84 | Mex$1,755.52 | n/a | 8 |
| Sep ’24 | n/a | Mex$1,956.01 0% | 10.1% | Mex$2,431.10 | Mex$1,712.04 | n/a | 8 |
| Aug ’24 | n/a | Mex$1,765.92 0% | 6.5% | Mex$1,936.40 | Mex$1,616.48 | n/a | 8 |
| Jul ’24 | n/a | Mex$1,791.42 0% | 5.6% | Mex$1,965.34 | Mex$1,669.67 | Mex$2,535.00 | 8 |
| Jun ’24 | n/a | Mex$1,742.84 0% | 7.8% | Mex$1,969.66 | Mex$1,479.86 | n/a | 8 |
| May ’24 | n/a | Mex$1,624.98 0% | 7.8% | Mex$1,942.15 | Mex$1,526.75 | n/a | 8 |
| Apr ’24 | n/a | Mex$1,675.47 0% | 10.0% | Mex$2,050.73 | Mex$1,405.13 | n/a | 8 |
| Mar ’24 | n/a | Mex$1,631.47 0% | 11.4% | Mex$1,983.47 | Mex$1,359.05 | n/a | 6 |
| Feb ’24 | Mex$1,415.00 | Mex$1,592.20 +12.5% | 14.7% | Mex$2,088.56 | Mex$1,392.37 | n/a | 6 |
| Jan ’24 | n/a | Mex$1,576.31 0% | 15.3% | Mex$2,106.08 | Mex$1,404.05 | n/a | 6 |
| Dec ’23 | n/a | Mex$1,576.31 0% | 15.3% | Mex$2,106.08 | Mex$1,404.05 | n/a | 6 |
| Nov ’23 | Mex$1,415.00 | Mex$1,655.92 +17.0% | 14.6% | Mex$2,139.96 | Mex$1,426.64 | n/a | 7 |
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
Médica Sur. de
Mex$3.1b
Operates as a healthcare hospital in Mexico.
MEDICA B
Mex$28.84
7D
-0.6%
1Y
-31.0%
ZimVie
US$186.2m
Develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide.
ZIMV *
US$230.00
7D
0%
1Y
n/a
M3
JP¥880.0b
Provides medical-related services primarily to physicians and other healthcare professionals through Internet.
2413 N
JP¥183.50
7D
0%
1Y
n/a